MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31, TTRX had $6,141,527 increase in cash & cash equivalents over the period.

Cash Flow Overview

Change in Cash
$6,141,527
Unit: Dollar
Positive Cash Flow Breakdown
    • Proceeds from avenue capital loa...
    • Cash receipt from stock subscrip...
    • Amortization of deferred offerin...
    • Stock-based compensation expense
Negative Cash Flow Breakdown
    • Net gain from change in fair val...
    • Accounts payable and accrued exp...
    • Prepaids and other current asset...
    • Purchases of intangible assets

Cash Flow
2026-03-31
2025-12-31
2025-09-30
Net loss
-970,972 279,070 -3,473,150
Depreciation and amortization
-52,746 -
Amortization expense
-24,140 -38,591
Stock-based compensation expense
280,830 256,380 162,865
Non-cash operating lease expense
-1,172 -
Common stock issued in exchange for services
-0 250,000
Net gain from change in fair value of derivative liability instruments
697,561 2,574,971 -
Gain from change in fair value of forward contract liability
--380,442 -
Non-cash operating lease effect
--1,165
Amortization of deferred offering cost
477,647 496,948 -
Prepaids and other current assets
123,738 -68,283 -36,742
Accounts payable and accrued expenses
-613,464 664,303 1,597,153
Net cash used in operating activities
-1,632,807 -1,176,267 -1,386,634
Purchases of intangible assets
12,227 31,441 121,545
Net cash used in investing activities
-12,227 -31,441 -121,545
Cash receipt from stock subscription receivable
1,070,000 --
Proceeds from issuance of stock, net of issuance costs
-3,177,696 3,741,736
Proceeds from avenue capital loan agreement
6,716,561 --
Net cash provided by financing activities
7,786,561 3,177,696 3,741,736
Net increase (decrease) in cash and cash equivalents
6,141,527 1,969,988 2,233,557
Cash and cash equivalents at beginning of the period
5,076,144 3,106,156 872,599
Cash and cash equivalents at end of the period
11,217,671 5,076,144 3,106,156
Unit: Dollar. Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from avenuecapital loan agreement$6,716,561 Cash receipt fromstock subscription...$1,070,000 Net cash provided byfinancing activities$7,786,561 Net increase(decrease) in cash and cash...$6,141,527 Canceled cashflow$1,645,034 Amortization of deferredoffering cost$477,647 Stock-based compensationexpense$280,830 Net cash used inoperating activities-$1,632,807 Net cash used ininvesting activities-$12,227 Canceled cashflow$758,477 Net loss-$970,972 Net gain from changein fair value of...$697,561 Purchases of intangibleassets$12,227 Accounts payable andaccrued expenses-$613,464 Prepaids and othercurrent assets$123,738

Turn Therapeutics Inc. (TTRX)

Turn Therapeutics Inc. (TTRX)